Home / Market / Company Snapshot

Shasun Pharmaceuticals Ltd

HSL Code: SHACHE | BSE Code: 524552 | NSE Symbol: SHASUNPHAR | ISIN: INE317A01028

Fetching Data...

research reports

Technical Stock Pick - Sun Pharma 11 Feb | 14:53
Sun Pharmaceutical made its all time high at Rs.776.
Q2FY13 Result Update - Sun Pharmaceutical Industries Ltd (SPIL) 16 Nov | 09:43
SPIL reported better than expected Q2FY13 results
Buy Shasun Pharmaceuticals at CMP and add on Dips. Place Stoploss of around Rs 80.50 7 May | 15:30
Stock pick Technicals Shasun Pharmaceuticals

news

May20	Corporate News on Monday 12:38 Shasun Pharmaceuticals - Board to consider Dividend 626651
Apr10	Corporate News on Wednesday 11:13 Shasun Pharmaceuticals and Debiopharm Group enter into licensing agreement 619317
Mar22	Corporate News on Friday 10:26 Shasun Pharmaceuticals` board approves conversion of warrants 616693
Mar13	Corporate News on Wednesday 15:32 Shasun Pharmaceuticals to consider conversion of warrants 615229
Feb7	Results - Announcements on Thursday 19:42 Shasun Pharmaceuticals net profit declines 77.21% in the December 2012 quarter 606610

Key Ratios

Market Cap (Rs. in Cr.)	411.48
Book Value	40.77
EPS (TTM)	12.87
Price/Book	1.83
Face value	2.00
P/E	5.65
Div(%)	20.00
Div Yield(%)	2.89

Fetching Data...

Rs. Cr.	Dec 12	Sep 12	Jun 12
Total Income	278.90	282.67	268.17
Total Expenses	250.88	241.42	233.01
EBITDA	28.02	41.25	35.16
EBIT	16.27	27.79	23.69
PBT	6.43	21.30	13.83
PAT	8.21	17.75	13.82
Net Profit	8.21	17.75	13.82

Values Based on Consolidated Data

Peer Group

More Compare

Lupin (NSE) 769.65(2.92%)
Divi`s Lab. (NSE) 989.40(0.99%)
Jubilant Life (NSE) 145.50(1.54%)
Shilpa Medicare (NSE) 293.30(2.89%)
Hikal (NSE) 408.90(-0.34%)

Shareholding Pattern

	Promoters	42.50%
	Mutual Funds / UTI	6.99%
	FI / Banks	0.32%
	Insurance	0.62%
	Government	0.00%
	FII	0.34%
	Others	49.24%

Announcements & Events

Announcements
events

May20	Shasun Pharmaceuticals - Board to consider Dividend
Apr10	Shasun Pharmaceuticals and Debiopharm Group enter into licensing agreement
Mar22	Shasun Pharmaceuticals` board approves conversion of warrants
Mar14	Shasun Pharmaceuticals To Consider Conversion Of Warrants
Sep25	Sun Pharmaceuticals received UK MHRA nod for the Zoledronic Acid

MF holdings

Scheme Name	%AUM	CMV(Rs. Cr)
Sundaram S.M.I.L.E Fund (D)	4.58	14.95
Sundaram Equity Multiplier Fund (G)	3.49	4.44
UTI-Mid Cap Fund (D)	0.78	2.10
Sundaram CAPEX Opportunities Fund (G)	1.15	1.82
Sundaram CAPEX Opportunities Fund (D)	1.09	1.55

Exchange Information

NSE Indices		BSE Indices
Nifty		Sensex
CNX 100		BSE 100
CNX 200		BSE 200
S&P CNX 500		BSE 500
CNX Midcap		BSE Mid-Cap
CNX Midcap 50		BSE Small-Cap

Note: The scrip is a constituent of those NSE and BSE indices that have against them.

Comparative performance

	1M (%)	3M (%)	6M (%)
Shasun Pharmaceuticals Ltd	-3.24	-12.54	-56.15
NIFTY (S&P CNX)	2.23	1.92	6.05
BSE Sensex	2.58	1.77	6.31
BSE 500	2.06	0.77	3.79

F & O Quotes

Futures
Options

Expiry Date

No Record Found.

Key Personnel
R Kannan Chairman S Abhaya Kumar Managing Director S Vimal Kumar Whole-time Director

Key Address

Registered Office:
Shasun Pharma.
Batra Centre 3rd & 4th Floor,
28 Sardar Patel Road Guindy,
Chennai,
Tamil Nadu.
Tel : 91-44-43446700
Fax : 91-44-22350924/22350278

Email : shasun:shasun.com
Website : http://www.shasun.com

Registrars Details
Integrated Enterprises (I) Ltd.
Add. :Kences Tower,
2nd Floor No 1, Ramakrishna Street,
Chennai - 600 017.